Kathleen Brady
Adult Health · Palm Coast, FLNPI 1568791630
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $921 and has fallen 91.6% since, to $77 in 2024.
Across 95 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$217
- Genentech USA, Inc.$123
- Johnson & Johnson$90
- AstraZeneca$85
- Bayer$78
- AbbVie$76
- plus $1K from 35 others
What the payments were for
- Food & beverage$1,70395%
- Education$905%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $217 |
| Genentech USA, Inc. | 7 | $123 |
| Johnson & Johnson | 1 | $90 |
| AstraZeneca | 4 | $85 |
| Bayer | 4 | $78 |
| AbbVie | 3 | $76 |
| Seagen Inc. | 4 | $71 |
| Eisai Inc. | 3 | $69 |
| Sanofi | 4 | $67 |
| Astellas Pharma US Inc | 3 | $59 |
| Tersera Therapeutics LLC | 3 | $56 |
| Incyte Corporation | 2 | $51 |
| Gilead(2 entities) | 2 | $50 |
| Array Biopharma Inc | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| CTI Biopharma Corp. | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Puma Biotechnology, Inc. | 2 | $37 |
| Morphosys, US Inc. | 2 | $35 |
| Pfizer | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| GSK | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 2 | $26 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $23 |
| Acrotech Biopharma Inc. | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
How this compares
$1,793 in reported general payments places this provider in the 75th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 13 | $128 |
Paid to pharmacies, not to this prescriber.
Other adult health in Palm Coast
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.